AstraZeneca is a global biopharmaceutical company, formed in 1999, that discovers and commercialises therapies in oncology, biopharmaceuticals, respiratory and rare diseases, working in precision medicine, AI and data science.
AstraZeneca is a global biopharmaceutical company formed in 1999 from the merger of Astra AB of Sweden and Zeneca Group PLC of the United Kingdom. It discovers, develops and commercialises therapies across oncology, biopharmaceuticals, respiratory and rare diseases, with an emphasis on precision medicine and next-generation therapeutics. Technical work spans data science, artificial intelligence, cell therapies and pharmaceutical R&D.
The company's scale is considerable. Its portfolio contains 16 blockbuster medicines, and its development pipeline comprises 197 projects, supported by billions invested in R&D annually and six strategic R&D centres. The stated ambition is to deliver 20 new medicines by 2030.
Research and commercial operations are anchored in Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai and Beijing, among other locations, spanning Sweden, the United Kingdom and China. The organisation describes itself as values-driven since the 1999 merger, with a stated commitment to following the science and putting patients first in its decision making.
